United States Patent 9,265,740: A Comprehensive Analysis
Overview of the Patent
The United States Patent 9,265,740, titled "Minocycline compounds and methods of use thereof," was issued on February 23, 2016, to Paratek Pharmaceuticals, Inc. This patent is part of a broader portfolio of intellectual property related to minocycline compounds and their therapeutic applications.
Inventors and Assignees
The inventors listed on this patent include Sean M. Johnston, Robert D. Arbeit, Thomas J. Bigger, Dennis P. Molnar, and S. Ken Tanaka. The assignee is Paratek Pharmaceuticals, Inc., a company known for its work in developing innovative antibiotics[2][3].
Scope of the Patent
Minocycline Compounds
The patent focuses on specific minocycline compounds, particularly 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline and its salts. These compounds are derivatives of the tetracycline antibiotic minocycline, which is known for its broad-spectrum antibacterial activity[1][4].
Methods of Use
The patent describes methods for treating various bacterial infections using these minocycline compounds. The infections include, but are not limited to, Methicillin-Susceptible Staphylococcus aureus (MSSA), Methicillin-Resistant Staphylococcus aureus (MRSA), and other bacterial infections such as cellulitis, abscesses, and wounds[1][4].
Claims of the Patent
Therapeutic Applications
The patent claims cover the use of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline and its salts for treating a range of bacterial infections. These applications include:
- Community-Acquired Bacterial Pneumonia (CABP): The compound is effective in treating CABP, a common and serious infection[2][4].
- Skin and Skin Structure Infections: Complicated skin and skin structure infections, such as cellulitis and abscesses, are also targeted by this compound[4].
- Wounds and Injuries: The patent includes claims for treating wounds and injuries caused by bacterial infections[1].
Administration Methods
The patent covers various methods of administering these compounds, including:
- Oral Administration: The compound can be administered orally in the form of tablets or capsules.
- Intravenous Administration: It can also be administered intravenously, providing flexibility in treatment options[1][3].
Pharmaceutical Compositions
The patent describes pharmaceutical compositions that include the minocycline compounds. These compositions may be formulated to enhance bioavailability, stability, and patient compliance. The compositions can include various salts and polymorphs of the compound, which are designed to optimize therapeutic efficacy[1][3].
Patent Expiration Dates
The patent is set to expire on March 5, 2029. However, the overall patent landscape for Nuzyra, the drug that utilizes these minocycline compounds, extends until October 31, 2037, due to additional patents and exclusivities granted by the FDA[2][3].
Related Patents and Exclusivities
Other Relevant Patents
Several other patents related to Nuzyra and its active ingredients are part of the broader patent landscape. These include:
- US8383610: Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline.
- US7553828: 9-aminomethyl substituted minocycline compounds.
- US10383884: 9-aminomethyl minocycline compounds and use thereof in treating CABP[3].
FDA Exclusivities
In addition to the patent protection, Nuzyra has been granted several FDA exclusivities, which prevent other companies from marketing generic or bioequivalent versions of the drug until these exclusivities expire. These exclusivities play a crucial role in delaying the generic launch of Nuzyra[3].
Impact on the Pharmaceutical Industry
The patent and its related intellectual property have significant implications for the pharmaceutical industry:
- Innovation in Antibiotics: The development of new minocycline compounds addresses the growing need for effective antibiotics against resistant bacterial strains.
- Market Protection: The patent and exclusivities provide Paratek Pharmaceuticals with a competitive advantage, protecting their investment in research and development.
- Therapeutic Options: The availability of these compounds expands the therapeutic options for healthcare providers, particularly in treating complex bacterial infections[1][2][3].
Key Takeaways
- Specific Compounds: The patent focuses on 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline and its salts.
- Therapeutic Applications: It covers treatments for various bacterial infections, including CABP and skin infections.
- Administration Methods: Both oral and intravenous administration methods are described.
- Patent Expiration: The patent expires on March 5, 2029, but related patents and exclusivities extend protection until October 31, 2037.
- Industry Impact: The patent contributes to innovation in antibiotics and provides market protection for Paratek Pharmaceuticals.
FAQs
What is the main compound described in US Patent 9,265,740?
The main compound is 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline and its salts.
What are the primary therapeutic applications of this patent?
The primary therapeutic applications include treating Community-Acquired Bacterial Pneumonia (CABP), skin and skin structure infections, and other bacterial infections.
How can the minocycline compounds be administered?
The compounds can be administered orally in the form of tablets or capsules, or intravenously.
When does the patent expire?
The patent expires on March 5, 2029, but related patents and exclusivities extend protection until October 31, 2037.
Who is the assignee of this patent?
The assignee is Paratek Pharmaceuticals, Inc.
Cited Sources
- US Patent 9,265,740 - Minocycline compounds and methods of use thereof[1].
- Generic Nuzyra Availability - Drugs.com[2].
- Nuzyra patent expiration - Pharsight[3].
- US Patent 10,111,890 - 9-aminomethyl minocycline compounds and uses thereof[4].
